Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study

Since our previous study has shown that some personality dimensions were associated with Quality of Life (QoL) amelioration after Deep Brain Stimulation (DBS) in Parkinson's disease (PD), the investigators aim to evaluate the impact of personality dimensions on therapeutic response after another second-line treatment: the continuous subcutaneous apomorphine infusion (CSAI). Moreover, the investigators would like to evaluate the potential evolution of personality dimensions through CSAI. The investigators also aim to evaluate other bio-psycho-social factors (representations of the disease, ways of copying and social support) influence on QoL amelioration after DBS.

Start Date15 Feb 2024

Sponsor / Collaborator

Toulouse University Hospital

[+2]

NCT00040209 / CompletedPhase 2IIT

Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease

This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. JP-1730 affects chemical messengers believed to affect Parkinson's disease symptoms.
Patients between 30 and 80 years of age with relatively advanced Parkinson's disease may be eligible for this 3-phase study.
Phase 1 - Baseline evaluation
Participants will be evaluated with a medical history, physical examination, detailed neurologic evaluation, routine blood tests, urinalysis and an electrocardiogram. They will also have a 24-hour holter monitor (heart monitoring) and cardiology consultation. A chest X-ray and MRI or CT scan of the brain will be done if needed. Patients will, if possible, stop taking all antiparkinsonian medications except levodopa (Sinemet) for one month before the study begins and throughout its duration. (If necessary, patients may use short-acting dopamine agonists, such as Mirapex and Requip.)
Phase 2 - Dose Finding Phase
For 2 to 3 days, patients will be admitted to the NIH Clinical Center for a levodopa (a dopamine agonist) dose-finding procedure. For this procedure, patients stop taking Sinemet and instead have levodopa, and subsequently apomorphine, infused through a vein. During the infusions, the drug dose is increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Symptoms are monitored frequently to find the optimal dose. (Patients who have had dosing infusions in the last 3 months will not have to undergo this phase of the study.)
Phase 3 - Active Study Phase
Within 3 months of the dose-finding phase, treatment will begin. Patients will receive seven doses of JD-1730 or placebo (an inactive substance) via puffs from an oral spray together with levodopa infusions over a 3-week period. The doses are given on days 1, 2, and 3 of the first week and then approximately twice a week for the next 2 weeks. For these doses, patients are hospitalized 4 days the first week and 2 days each for the next 2 weeks. All participants will receive placebo at some time during the study, and a few patients, selected at random, will receive only placebo the entire 3 weeks. The procedure for the infusions is the same as that for the dose-finding phase, with frequent evaluation of symptoms. Also, small blood samples are drawn up to three times each study day. At the end of the third week, patients will be discharged from the hospital. Their anti-parkinsonian medications may be readjusted, as needed. Patients will be contacted 2 weeks after the end of the study for a check on side effects and, if necessary, will be scheduled for a follow-up evaluation at the clinic.
In addition to the above procedures, patients will be asked to have an optional lumbar a puncture (spinal tap) on the first and last days of the study to measure various brain chemicals and drug levels that cannot be measured in blood and urine. For this procedure, a local anesthetic is given and a needle is inserted in the space between the bones (vertebrae) in the lower back. About 2 tablespoons of fluid is collected through the needle.

Start Date01 Jun 2002

Sponsor / Collaborator

National Institute of Neurological Disorders & Stroke

100 Clinical Results associated with NH-001

100 Translational Medicine associated with NH-001

100 Patents (Medical) associated with NH-001

9,835

Literatures (Medical) associated with NH-001

01 Feb 2025·Neural Regeneration Research

Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease

Article

Author: Berthiaume, Line ; Julien, Pierre ; Calon, Frédéric ; Saint-Pierre, Martine ; Kerdiles, Olivier ; Oye Mintsa Mi-Mba, Méryl-Farelle ; Cicchetti, Francesca ; Coulombe, Katherine ; Tremblay, Cyntia ; Rouxel, Clémence ; Émond, Vincent

JOURNAL/nrgr/04.03/01300535-202502000-00033/figure1/v/2024-11-07T113602Z/r/image-tiff There is a need to develop interventions to slow or reverse the degeneration of dopamine neurons in Parkinson’s disease after diagnosis. Given that preclinical and clinical studies suggest benefits of dietary n-3 polyunsaturated fatty acids, such as docosahexaenoic acid, and exercise in Parkinson’s disease, we investigated whether both could synergistically interact to induce recovery of the dopaminergic pathway. First, mice received a unilateral stereotactic injection of 6-hydroxydopamine into the striatum to establish an animal model of nigrostriatal denervation. Four weeks after lesion, animals were fed a docosahexaenoic acid-enriched or a control diet for the next 8 weeks. During this period, the animals had access to a running wheel, which they could use or not. Docosahexaenoic acid treatment, voluntary exercise, or the combination of both had no effect on (i) distance traveled in the open field test, (ii) the percentage of contraversive rotations in the apomorphine-induction test or (iii) the number of tyrosine-hydroxylase-positive cells in the substantia nigra pars compacta. However, the docosahexaenoic acid diet increased the number of tyrosine-hydroxylase-positive terminals and induced a rise in dopamine concentrations in the lesioned striatum. Compared to docosahexaenoic acid treatment or exercise alone, the combination of docosahexaenoic acid and exercise (i) improved forelimb balance in the stepping test, (ii) decreased the striatal DOPAC/dopamine ratio and (iii) led to increased dopamine transporter levels in the lesioned striatum. The present results suggest that the combination of exercise and docosahexaenoic acid may act synergistically in the striatum of mice with a unilateral lesion of the dopaminergic system and provide support for clinical trials combining nutrition and physical exercise in the treatment of Parkinson’s disease.

01 Dec 2024·European Journal of Pharmacology

AdipoRon improves mitochondrial homeostasis and protects dopaminergic neurons through activation of the AMPK signaling pathway in the 6-OHDA-lesioned rats

Article

Author: Mohaddes, Gisou ; Athari, Seyed Zanyar ; Azizifar, Negin ; Karimipour, Mohammad ; Farajdokht, Fereshteh ; Alimohammadi, Soraya ; Keyhanmanesh, Rana

The progressive decline of dopaminergic neurons in Parkinson's disease (PD) has been linked to an imbalance in energy and the failure of mitochondrial function. AMP-activated protein kinase (AMPK), the major intracellular energy sensor, regulates energy balance, and damage to nigral dopaminergic neurons induced by 6-hydroxydopamine (6-OHDA) is exacerbated in the absence of AMPK activity. This study aimed to examine the potential therapeutic advantages of AdipoRon, an AMPK activator, on motor function and mitochondrial homeostasis in a 6-OHDA-induced PD model. Male Wistar rats were subjected to unilateral injection of 6-OHDA (10 μg) into the left medial forebrain bundle at two points, and after 7 days, they were treated with intranasal AdipoRon (0.1, 1, and 10 μg) or Levodopa (10 mg/kg, p. o.) for 21 successive days. Following the last treatment day, motor behavior was evaluated through the Murprogo's test, bar test, beam walking test, and apomorphine-induced rotation test. After euthanasia, the left substantia nigra (SN) was separated for evaluation of ATP, mitochondrial membrane potential (MMP), and protein expressions of AMPK, p-AMPK, and mitochondrial dynamics markers (Mfn-2 and Drp-1). Moreover, the number of tyrosine hydroxylase-positive (TH⁺) cells was quantified in the left substantia nigra. Intranasal AdipoRon effectively reversed muscle rigidity, akinesia, bradykinesia, and rotation caused by 6-OHDA. Moreover, AdipoRon increased the phospho-AMPK/AMPK ratio, mitigated mitochondrial dysfunction, and improved mitochondrial dynamics in the SN. Furthermore, AdipoRon increased the number of TH⁺ cells in the SN of PD animals. These findings suggest that AdipoRon could protect dopaminergic neurons by activating the AMPK pathway and improving mitochondrial dysfunction.

01 Nov 2024·Experimental Neurology

Emission of 50-kHz ultrasonic vocalizations stimulated by antiparkinsonian dopaminomimetic drugs in hemiparkinsonian rats is associated with neuronal activation in subcortical regions that regulate the affective state

Article

Author: Serra, Marcello ; Marongiu, Jacopo ; Simola, Nicola ; Costa, Giulia

Dopamine replacement therapy (DRT) of Parkinson's disease (PD) may trigger non-motor complications, some of which affect hedonic homeostatic regulation. Management of iatrogenic alterations in the affective state in PD is unsatisfactory, partly because of the limitations in the experimental models that are used in the preclinical investigation of the neurobiology and therapy of these alterations. In this connection, we recently employed a new experimental approach consisting in measuring the emission of 50-kHz ultrasonic vocalizations (USVs), a marker of positive affect, in hemiparkinsonian rats treated with drugs used in the DRT of PD. To further strengthen our approach, we here evaluated how the acute and repeated (× 5, on alternate days) administration of apomorphine (2 mg/kg, i.p.) or L-3,4-dihydroxyphenilalanine (L-DOPA, 12 mg/kg, i.p.) modified the immunoreactivity for Zif-268, a marker of neuronal activation, in the nucleus accumbens (NAc), caudate-putamen (CPu) and medial prefrontal cortex (mPFC), which are brain regions that regulate emotional states and drugs' affective properties. Acute and repeated treatment with either apomorphine or L-DOPA stimulated the emission of 50-kHz USVs in hemiparkinsonian rats, and this effect was paired with increased Zif-268 immunoreactivity in the NAc and CPu, but not mPFC. These findings indicate that subcortical and cortical regions may differently regulate the emission of 50-kHz USVs in hemiparkinsonian rats treated with dopaminergic drugs used in the DRT of PD. Moreover, they provide further evidence that measuring 50-kHz USV emissions in hemiparkinsonian rats may be a relevant approach to investigate at the preclinical level the affective properties of antiparkinsonian drugs.

News (Medical) associated with NH-001

12 Jun 2023

·www.globenewswire.com

Oncotelic Launches PR Chatbot

AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press releases (“PR”) chatbot. This chatbot is set to redefine user interaction by providing interactive responses to all our press releases through April 24, 2023. Our PR chatbot is open to all users, with no restriction on token holder status, thus inviting everyone to experience the seamless comparison of our PR chatbot with traditional ChatGPT. You can explore this firsthand on our website, as shown below. As we refine and perfect our beta version of our PR chatbot, your insights and feedback are invaluable. We welcome your thoughts at token@pet2dao.com. "We are thrilled to introduce our second chatbot to the world, says Scott Myers, Product Manager. Our commitment to developing cutting-edge AI technologies remains strong, and though this may seem a small step, we are working fervently on advancements in the background." Saran Saund, CBO of Oncotelic, shared his perspective, " Launching this chatbot marks another milestone in our ongoing commitment to harness the power of AI technologies. Even as this new development comes to the forefront, it's crucial to note that it's just one piece of a broader and more complex innovation landscape we are diligently working to shape behind the scenes The Company’s PR chatbot can be accessed at https://chat-pr.pet2dao.com/ The Company’s SEC chatbot can be accessed at https://chat-sec.pet2dao.com/ If you run into program access or use issues related to the PR chatbot, please reach out to token@pet2dao.com About Pet2DAO Launched in late 2022, Pet2DAO is a technology company using AI and Blockchain to blend traditional corporate governance with innovative DAO architecture. Starting with the animal health industry, it aims to streamline corporate operations by introducing cutting-edge technologies. Pet2DAO engages various stakeholders, from key opinion leaders and end users to medical professionals, treatment developers, and product manufacturers. By leveraging its proposal platform, it offers an efficient way for users to express their views and enhance communication. To continue its path of innovation, Pet2DAO integrates AI-powered chatbots for swift, user-friendly interactions, aiming to shape the future of corporate architecture. About Oncotelic Oncotelic Therapeutics Inc. (formerly known as Mateon Therapeutics, Inc.), initially formed as OXiGENE, Inc. in New York in 1988, reincorporated in Delaware in 1992, and underwent name changes in 2016 and 2020. Oncotelic aims to leverage its expertise in oncology drug development to enhance treatment outcomes, particularly for rare pediatric cancers. The company has rare pediatric designations for conditions such as Diffuse Intrinsic Pontine Glioma (through OT-101), melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI-driven biotech company and, in the fourth quarter of 2021, acquired AL-101 for intranasal apomorphine delivery. The company intends to develop AL-101 to treat Parkinson's Disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder. For more details on AL-101, refer to the Annual Report on form 10-K filed with the SEC on April 15, 2022. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2Dao, the actual filing of a registration statement and approval of the tokens as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2022 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information:For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

Acquisition

16 May 2023

·www.biospace.com

Oncotelic Participating at 2023 BIO International Convention

AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases such as Parkinson's Disease and various forms of cancer, is thrilled to announce their participation in the BIO International Convention. The Company's presentation is readily accessible at Key points of the presentation include: The significant role of TGF-β2 as the primary driver of survival, outpacing the influence of TGF-β1 and TGF-β3. The ongoing advancement of clinical trials for OT-101 in conjunction with P201 in Pancreatic Cancer, set to commence in the second half of 2023. Additional combination trials with various checkpoint inhibitors involving multiple cancer types are also slated to begin within the same timeframe. The sustained progress towards the IPO of the joint venture, contingent on favorable market conditions. The evolution of a state-of-the-art AI-driven nanomedicine platform designed to bolster both internal developmental processes and external collaborative endeavors. "Our commitment to innovation is reflected in the development of a cutting-edge AI-driven nanomedicine platform. This platform is anticipated to revolutionize the drug development initiatives within both Oncotelic and the joint venture. We are stand ready to invest in our partners supporting their journey from initial concept to clinical trials and through to commercialization," stated Dr. Vuong Trieu, CEO of Oncotelic and CEO of Sapu. We extend a warm invitation to all interested parties to explore the details of our presentation and discover more about the future of our groundbreaking work in rare and orphan disease therapeutics. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2Dao, the actual filing of a registration statement and approval of the tokens as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.: Investor Relations ir@oncotelic.com

AcquisitionClinical Study

25 Apr 2023

·www.globenewswire.com

Oncotelic Launches PDAO SEC Chatbot

AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary SEC chatbot, utilizing our DAO token (PDAO) and Artificial Intelligence (AI). This chatbot allows users to receive conversational responses about the Company's SEC filings filed as of April 12, 2023. Only holders of the Pet2DAO token, PDAO, can access the chatbot. Users can compare our SEC chatbot with traditional ChatGPT, on the website shown below. This beta version aims to improve with your inputs. Users are requested to send their feedback to token@pet2dao.com. "Through the innovative combination of DAO architecture and large language models like ChatGPT, users now can engage and have conversations with our SEC chatbot to explore Oncotelic SEC filings. We're excited about building shareholder value around PDAO " stated Scott Myers, Investor Relations. "I'm thrilled by the SEC chatbot's progress, even in its beta stage. The team has worked diligently to integrate DAO architecture within the Company, and the SEC chatbot exemplifies the potential of PDAO and AI," said Saran Saund, CBO of Oncotelic. "We're eager to launch more chatbots with diverse functionalities soon!" The Company’s SEC chatbot can be accessed at http://chat.pet2dao.com/ If you run into program access or use issues related to the SEC chatbot, please reach out to token@pet2dao.com About Pet2DAO Pet2DAO was launched in late 2022 and is DAO technology company that integrates traditional corporate governance with innovative DAO architecture using AI and Blockchain technologies. Pet2DAO aims to streamline corporate operations, starting with the animal health industry, by bringing new and innovative technologies to the market. Pet2DAO plans to engage all industry stakeholders, including key opinion leaders, end users, medical professionals, treatment developers, and product manufacturers. Pet2DAO plans to use its proposal platform to provide users with an efficient way to voice their opinions and streamline communications. Pet2DAO's vision is to continue innovating by incorporating AI through exclusive chatbots that provide quick, user-friendly conversational answers, with a broader goal of creating the corporate architecture of the future. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2Dao, the actual filing of a registration statement and approval of the tokens as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.: Investor Relations ir@oncotelic.com

Acquisition

100 Deals associated with NH-001

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00714

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Injuries	Phase 2	-	NeuroHealing Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTH-300 and CTH-302 (MDS2023)	Not Applicable	Hypotension, Orthostatic \| Parkinson Disease	240	Apomorphine sublingual film (SL-APO)	ycyoxpgyyj(aowsjsxytd) = wibovsuvgs hpjjydfcxu (fuljvwnhrm )	-	27 Aug 2023
MDS2022	Not Applicable	Hypotension, Orthostatic	-	Sublingual Apomorphine (SL-APO)	krcvazsiww(ssggerdbve) = szdvhppzzt nnccdyxnln (bavacdnatg ) View more	-	15 Sep 2022
MDS2022	Not Applicable	Hypotension, Orthostatic	-	Subcutaneous Apomorphine (SC-APO)	krcvazsiww(ssggerdbve) = ggewdrdqkn nnccdyxnln (bavacdnatg ) View more	-	15 Sep 2022
MDS2022	Not Applicable	-	7	Continuous subcutaneous apomorphine infusion (CSAI) <3mg per hour	ogjsxkfesl(qjvdgudrvx) = subcutaneous nodules, nausea, neuropsychiatric symptoms worsening cpoaaceazy (xyeihqxxed )	-	15 Sep 2022
MDS2019	Not Applicable	Parkinson Disease	312	Subcutaneous apomorphine	(mfyljlwyaz) = phnpqbeltq ovcojjmvkz (naxpnxwflx, -3.16 to -0.62)	Negative	22 Sep 2019
AAN2019	Phase 3	Parkinson Disease	-	Apomorphine sublingual film (APL)	(nydhnjhrws) = thfeevuhuv eocwdtapfs (kdrfoyzmkw ) View more	Positive	09 Apr 2019
MDS2016	Not Applicable	-	88	Apomorphine subcutaneous injections	hvvmgtdoxy(otuynsvtss) = hfxtjwgvll lbdblltfba (jequzexhvl ) View more	-	19 Jun 2016
EAN	Not Applicable	Camptocormia	-	Continuous subcutaneous infusions of apomorphine	sqtomfaikr(tbsnaepehy) = codxauwxzo unqkfbrrxv (cscbsknmzo )	-	29 Jun 2015
EAN	Not Applicable	Parkinson Disease	88	Apomorphine subcutaneous injections	uydbedaysn(cmljpwnrbh) = tuykishhri bgcrocdefe (qbeaifrzou, 14.55)	Positive	29 Jun 2015
EAN	Not Applicable	Parkinson Disease	88	L-dopa	uydbedaysn(cmljpwnrbh) = plxtyvwtbg bgcrocdefe (qbeaifrzou, 18.11)	Positive	29 Jun 2015
P1.189 (AAN2015)	Not Applicable	Parkinson Disease	127	Apomorphine subcutaneous injections	gaoimwmdvs(fwrrdwrlyk) = nnzlgqkvhu egwpbkfuul (emcmdxbafg, 14.82)	Positive	06 Apr 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis